Literature DB >> 14985335

A novel non-catalytic mechanism employed by the C-terminal Src-homologous kinase to inhibit Src-family kinase activity.

Yuh-Ping Chong1, Terrence D Mulhern, Hong-Jian Zhu, Donald J Fujita, Jeffrey D Bjorge, John-Paul Tantiongco, Nikolaos Sotirellis, Daisy Sio Seng Lio, Glen Scholz, Heung-Chin Cheng.   

Abstract

Although C-terminal Src kinase (CSK)-homologous kinase (CHK) is generally believed to inactivate Src-family tyrosine kinases (SFKs) by phosphorylating their consensus C-terminal regulatory tyrosine (Tyr(T)), exactly how CHK inactivates SFKs is not fully understood. Herein, we report that in addition to phosphorylating Tyr(T), CHK can inhibit SFKs by a novel non-catalytic mechanism. First, CHK directly binds to the SFK members Hck, Lyn, and Src to form stable protein complexes. The complex formation is mediated by a non-catalytic Tyr(T)-independent mechanism because it occurs even in the absence of ATP or when Tyr(T) of Hck is replaced by phenylalanine. Second, the non-catalytic CHK-SFK interaction alone is sufficient to inactivate SFKs by inhibiting the catalytic activity of autophosphorylated SFKs. Third, CHK and Src co-localize to specific plasma membrane microdomains of rat brain cells, suggesting that CHK is in close proximity to Src such that it can effectively inactivate Src in vivo. Fourth, native CHK.Src complex exists in rat brain, and recombinant CHK.Hck complex exists in transfected HEK293T cells, implying that CHK forms stable complexes with SFKs in vivo. Taken together, our findings suggest that CHK inactivates SFKs (i) by phosphorylating their Tyr(T) and (ii) by this novel Tyr(T)-independent mechanism involving direct binding of CHK to SFKs. It has been documented that autophosphorylated SFKs can still be active, in some cases even when their Tyr(T) is phosphorylated. Thus, the ability of the Tyr(T)-independent mechanism to suppress the activity of both non-phosphorylated and autophosphorylated SFKs represents a fail-safe measure employed by CHK to down-regulate SFK signaling under all circumstances.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14985335     DOI: 10.1074/jbc.M309865200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling.

Authors:  Liudmilla Rubbi; Björn Titz; Lauren Brown; Erica Galvan; Evangelia Komisopoulou; Sharon S Chen; Tracey Low; Martik Tahmasian; Brian Skaggs; Markus Müschen; Matteo Pellegrini; Thomas G Graeber
Journal:  Sci Signal       Date:  2011-03-29       Impact factor: 8.192

2.  IGF-I stimulates cooperative interaction between the IGF-I receptor and CSK homologous kinase that regulates SHPS-1 phosphorylation in vascular smooth muscle cells.

Authors:  Yashwanth Radhakrishnan; Xinchun Shen; Laura A Maile; Gang Xi; David R Clemmons
Journal:  Mol Endocrinol       Date:  2011-07-28

3.  Early emergence of negative regulation of the tyrosine kinase Src by the C-terminal Src kinase.

Authors:  Barbara Taskinen; Evandro Ferrada; Douglas M Fowler
Journal:  J Biol Chem       Date:  2017-09-22       Impact factor: 5.157

4.  Defining the substrate specificity determinants recognized by the active site of C-terminal Src kinase-homologous kinase (CHK) and identification of β-synuclein as a potential CHK physiological substrate.

Authors:  Kim K Ia; Grace R Jeschke; Yang Deng; Mohd Aizuddin Kamaruddin; Nicholas A Williamson; Denis B Scanlon; Janetta G Culvenor; Mohammed Iqbal Hossain; Anthony W Purcell; Sheng Liu; Hong-Jian Zhu; Bruno Catimel; Benjamin E Turk; Heung-Chin Cheng
Journal:  Biochemistry       Date:  2011-07-18       Impact factor: 3.162

5.  Control of excitatory synaptic transmission by C-terminal Src kinase.

Authors:  Jindong Xu; Manjula Weerapura; Mohammad K Ali; Michael F Jackson; Hongbin Li; Gang Lei; Sheng Xue; Chun L Kwan; Morris F Manolson; Kai Yang; John F Macdonald; Xian-Min Yu
Journal:  J Biol Chem       Date:  2008-04-29       Impact factor: 5.157

6.  p66shc inhibits insulin-like growth factor-I signaling via direct binding to Src through its polyproline and Src homology 2 domains, resulting in impairment of Src kinase activation.

Authors:  Gang Xi; Xinchun Shen; David R Clemmons
Journal:  J Biol Chem       Date:  2010-01-04       Impact factor: 5.157

Review 7.  Fyn kinase function in lipid utilization: a new upstream regulator of AMPK activity?

Authors:  Manu Vatish; Eijiro Yamada; Jeffrey E Pessin; Claire C Bastie
Journal:  Arch Physiol Biochem       Date:  2009-10       Impact factor: 4.076

8.  CSK-homologous kinase (CHK/MATK) is a potential colorectal cancer tumour suppressor gene epigenetically silenced by promoter methylation.

Authors:  Anderly C Chüeh; Gahana Advani; Momeneh Foroutan; Jai Smith; Nadia Ng; Harshal Nandurkar; Daisy S Lio; Hong-Jian Zhu; Yuh-Ping Chong; Heather Verkade; Donald J Fujita; Jeffrey Bjorge; Faiza Basheer; Jet Phey Lim; Ian Luk; Amardeep Dhillon; Anuratha Sakthianandeswaren; Dmitri Mouradov; Oliver Sieber; Frédéric Hollande; John M Mariadason; Heung-Chin Cheng
Journal:  Oncogene       Date:  2021-03-25       Impact factor: 9.867

Review 9.  Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells.

Authors:  Ashleigh R Poh; Robert J J O'Donoghue; Matthias Ernst
Journal:  Oncotarget       Date:  2015-06-30

Review 10.  The role of Src kinase in macrophage-mediated inflammatory responses.

Authors:  Se Eun Byeon; Young-Su Yi; Jueun Oh; Byong Chul Yoo; Sungyoul Hong; Jae Youl Cho
Journal:  Mediators Inflamm       Date:  2012-11-11       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.